Evidence supporting the use of: Polyunsaturated fatty acid
For the health condition: Parkinson's Disease

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Polyunsaturated fatty acids (PUFAs), especially omega-3 fatty acids such as EPA and DHA, have been investigated for their potential role in supporting or treating Parkinson’s Disease (PD). Scientific interest is based on the anti-inflammatory and neuroprotective properties of PUFAs, as neuroinflammation and oxidative stress are key contributors to the progression of PD. Some preclinical studies in animal models suggest that omega-3 PUFAs may help reduce neurodegeneration and improve motor symptoms. Observational epidemiological studies have also found that higher dietary intake of PUFAs is associated with a lower risk of developing PD or milder symptoms. However, human clinical trials are limited and results are inconclusive. A few small-scale, randomized controlled trials have examined omega-3 supplementation in PD patients, but improvements in motor function or disease progression have not been consistently demonstrated. Systematic reviews and meta-analyses conclude that while there is biological plausibility and some preliminary evidence, robust clinical evidence supporting the use of PUFAs to treat or slow Parkinson’s Disease is lacking. Thus, while their use is scientifically motivated, current evidence is weak to moderate, and further high-quality clinical trials are needed before strong recommendations can be made.

More about Polyunsaturated fatty acid
More about Parkinson's Disease

Products containing Polyunsaturated fatty acid

We currently have no products on Vitabase that contain this ingredient.